Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Total Liabilities (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Total Liabilities for 8 consecutive years, with $9.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Liabilities fell 41.48% to $9.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $9.8 million, a 41.48% decrease, with the full-year FY2024 number at $17.8 million, down 34.48% from a year prior.
  • Total Liabilities was $9.8 million for Q3 2025 at Whitehawk Therapeutics, up from $8.8 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $27.2 million in Q4 2023 to a low of $2.1 million in Q1 2021.
  • A 5-year average of $17.6 million and a median of $19.8 million in 2023 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: soared 801.5% in 2022, then crashed 61.65% in 2025.
  • Whitehawk Therapeutics' Total Liabilities stood at $21.5 million in 2021, then grew by 20.25% to $25.9 million in 2022, then rose by 5.29% to $27.2 million in 2023, then plummeted by 34.48% to $17.8 million in 2024, then tumbled by 44.8% to $9.8 million in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Total Liabilities are $9.8 million (Q3 2025), $8.8 million (Q2 2025), and $12.3 million (Q1 2025).